UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login